[Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome]. 1989

J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
Service d'Hépato-Gastroentérologie, Hôpital Bichat, Paris.

Omeprazole efficacy and tolerance were evaluated in 20 patients with longstanding Zollinger-Ellison syndrome (ZES) committed to long-term antisecretory therapy. The study included 13 men and 7 women, aged 53 (30-74) years (median and range). Nineteen patients presented with epigastric pain, 14 with vomiting, and 9 with diarrhea. All patients had gastroduodenal ulcerations, associated with esophagitis in 9 cases. Median and extreme values for basal acid output (BAO) and serum gastrin (SG) levels before omeprazole treatment were 41 (3.7-80) mmol H+/h and 413 (111-11,490) pg/ml, respectively. In 18 patients, omeprazole treatment was initiated because of resistance to H2-antagonists, and in 2 patients because of carbothioamide RP 40749 discontinuation. Initial doses of omeprazole were 60 mg per day in 10 patients and ranged from 80 to 160 mg per day in the others. Esophagogastrectomy was performed in one patient at day 15 because of esophageal stenosis. In the remaining 19 patients, median duration of treatment was 16 (7-54) months and median doses of omeprazole were 70 (20-160) mg per day during the survey. Omeprazole therapy was highly effective in inducing rapid disappearance of clinical abnormalities in 18 of 19 patients. Twenty-two days after initiation of treatment, median BAO was 4 (0-14) mmol/h and ulcerations had healed in 17 of 19 patients. Median BAO was less than 5 mmol/h during follow-up. However, asymptomatic ulcer recurrence was noted in 4 patients, but disappeared quickly after omeprazole doses were increased. Median basal gastrin level was 700 (116-36.625) pg/ml at the least determination and was statistically higher than pretreatment values (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D004064 Digestive System A group of organs stretching from the MOUTH to the ANUS, serving to breakdown foods, assimilate nutrients, and eliminate waste. In humans, the digestive system includes the GASTROINTESTINAL TRACT and the accessory glands (LIVER; BILIARY TRACT; PANCREAS). Ailmentary System,Alimentary System
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D005755 Gastrins A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters. Gastrin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
October 1989, Gastroenterology,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
April 1989, Lancet (London, England),
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
April 1991, Digestive diseases and sciences,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
April 1986, Scandinavian journal of gastroenterology,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
July 1990, Gastroenterology,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
April 1993, Alimentary pharmacology & therapeutics,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
March 1985, Ugeskrift for laeger,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
March 1986, L'union medicale du Canada,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
July 1993, Digestive diseases and sciences,
J F Cadranel, and P Ruszniewski, and L Elouaer-Blanc, and T Lehy, and J C Delchier, and G Cadiot, and C Florent, and J Vatier, and M Mignon
August 1996, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!